- Home
- VIVS vs QNRX Comparison
VIVS vs QNRX Comparison
Compare VIVS & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- QNRX
- Stock Information
- Founded
- VIVS 2007
- QNRX 2018
- Country
- VIVS United States
- QNRX United States
- Employees
- VIVS N/A
- QNRX 3
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- QNRX Medical/Dental Instruments
- Sector
- VIVS Health Care
- QNRX Health Care
- Exchange
- VIVS Nasdaq
- QNRX Nasdaq
- Market Cap
- VIVS 4.7M
- QNRX 4.8M
- IPO Year
- VIVS N/A
- QNRX N/A
- Fundamental
- Price
- VIVS $3.64
- QNRX $8.59
- Analyst Decision
- VIVS
- QNRX
- Analyst Count
- VIVS 0
- QNRX 0
- Target Price
- VIVS N/A
- QNRX N/A
- AVG Volume (30 Days)
- VIVS 868.7K
- QNRX 107.3K
- Earning Date
- VIVS 11-07-2025
- QNRX 11-06-2025
- Dividend Yield
- VIVS N/A
- QNRX N/A
- EPS Growth
- VIVS N/A
- QNRX N/A
- EPS
- VIVS N/A
- QNRX N/A
- Revenue
- VIVS $142,000.00
- QNRX N/A
- Revenue This Year
- VIVS $42.38
- QNRX N/A
- Revenue Next Year
- VIVS $15.42
- QNRX N/A
- P/E Ratio
- VIVS N/A
- QNRX N/A
- Revenue Growth
- VIVS 94.52
- QNRX N/A
- 52 Week Low
- VIVS $1.41
- QNRX $5.01
- 52 Week High
- VIVS $21.96
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- VIVS 62.00
- QNRX 70.88
- Support Level
- VIVS $3.29
- QNRX $7.35
- Resistance Level
- VIVS $5.30
- QNRX $7.79
- Average True Range (ATR)
- VIVS 0.63
- QNRX 0.38
- MACD
- VIVS 0.16
- QNRX 0.13
- Stochastic Oscillator
- VIVS 52.16
- QNRX 46.79
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.